4194 Stock Overview
Develops therapeutics in Taiwan. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Holy Stone Healthcare Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NT$12.30 |
| 52 Week High | NT$25.00 |
| 52 Week Low | NT$11.90 |
| Beta | 1.38 |
| 1 Month Change | -16.89% |
| 3 Month Change | -29.71% |
| 1 Year Change | -36.80% |
| 3 Year Change | -57.58% |
| 5 Year Change | 4.83% |
| Change since IPO | -88.08% |
Recent News & Updates
Recent updates
Shareholder Returns
| 4194 | TW Biotechs | TW Market | |
|---|---|---|---|
| 7D | -2.4% | 2.0% | 0.4% |
| 1Y | -36.8% | 1.6% | 28.7% |
Return vs Industry: 4194 underperformed the TW Biotechs industry which returned 1.6% over the past year.
Return vs Market: 4194 underperformed the TW Market which returned 28.7% over the past year.
Price Volatility
| 4194 volatility | |
|---|---|
| 4194 Average Weekly Movement | 5.4% |
| Biotechs Industry Average Movement | 4.5% |
| Market Average Movement | 4.4% |
| 10% most volatile stocks in TW Market | 7.8% |
| 10% least volatile stocks in TW Market | 2.1% |
Stable Share Price: 4194 has not had significant price volatility in the past 3 months compared to the TW market.
Volatility Over Time: 4194's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2001 | n/a | Albert Wu | www.hshc.com.tw |
Holy Stone Healthcare Co., Ltd. develops therapeutics in Taiwan. It offers RenehaVis, a product designed to relive pain and stiffness of the knee joint; SportVis, a treatment to relive the pain and optimize the recovery of tendon and ligament injuries; TRUD, a treatment that allows mucosal tissue to heal naturally and reduces the symptoms of ulcerative colitis; and GAF, a treatment for anal mucosal lesions. The company is also developing IBD98-M, which is in Phase IIa clinical trials for the treatment of inflammatory bowel diseases; and CA102N to treat colorectal cancer.
Holy Stone Healthcare Co., Ltd. Fundamentals Summary
| 4194 fundamental statistics | |
|---|---|
| Market cap | NT$1.80b |
| Earnings (TTM) | -NT$239.91m |
| Revenue (TTM) | NT$222.29m |
8.1x
P/S Ratio-7.5x
P/E RatioIs 4194 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4194 income statement (TTM) | |
|---|---|
| Revenue | NT$222.29m |
| Cost of Revenue | NT$133.15m |
| Gross Profit | NT$89.15m |
| Other Expenses | NT$329.05m |
| Earnings | -NT$239.91m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.64 |
| Gross Margin | 40.10% |
| Net Profit Margin | -107.93% |
| Debt/Equity Ratio | 0% |
How did 4194 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/24 00:00 |
| End of Day Share Price | 2024/12/24 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Holy Stone Healthcare Co., Ltd. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|